Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10.5
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and raises the price target from $10 to $10.5.
Markets · News reference
8-K filing — GS Mortgage Securities Trust 2015-GC30
Filed: 2026-09-08 AccNo: 0001853620-26-000211 Size: 26 KB Item 6.02: Change of Servicer or Trustee
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
No ticker was attached by the source feed.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Hooker Furnishings Q2 EPS $0.12 Beats $(0.02) Estimate, Sales $63.250M Miss $63.761M Estimate
Hooker Furnishings (NASDAQ:HOFT) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $(0.02) by 700 percent. This is a 138.71 percent increase over losses of $(0.31) per share
As the Rotation Dies, Wall Street Is Blaming the Wrong Flaw in Small Caps
Surging energy prices and rising yields stall market broadening, forcing a return to mega-cap tech and semiconductor dominance.
Ascendiant Capital Maintains Buy on Cerenome, Lowers Price Target to $43
Ascendiant Capital analyst Edward Woo maintains Cerenome (NASDAQ:CNSY) with a Buy and lowers the price target from $57 to $43.
Kestra Likely To Report Q1 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Kestra Medical Technologies will report its first earnings Sept. 14, with analysts expecting a $0.62 EPS loss and $29.01M revenue.
'JD.com Prepares Remedy Tweaks in Bid for EU Ceconomy Approval' - Bloomberg
https://www.bloomberg.com/news/articles/2026-09-11/jd-com-prepares-remedy-tweaks-in-bid-for-eu-ceconomy-approval